SCHEMBL645849

SCHEMBL645849

Oc1cccc2cc[c]cc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.54
CTDSP1 Q9GZU7 1/20 0.44
PLAU P00749 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPKAPK2 P49137 1/20 0.39
TSHR P16473 3/20 0.38
HPGD P15428 2/20 0.38
ALOX15 P16050 2/20 0.38
RECQL P46063 2/20 0.38
HSD17B10 Q99714 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
APP P05067 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
CASP1 P29466 1/20 0.38
SNCA P37840 1/20 0.38
HSD17B1 P14061 4/20 0.37
HSD17B2 P37059 4/20 0.37
ESR1 P03372 2/20 0.37
ESR2 Q92731 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL384025 0.84 CYP1A2 (0.56) CYP1A2CTDSP1PLAUKDM4EMAPKAPK2
SCHEMBL2781984 0.77 ALDH1A1 (0.33) CYP1A2TSHRHPGDHSD17B10TDP1
SCHEMBL643662 0.74 MEN1 (0.33) KDM4EHPGDMEN1KMT2A
SCHEMBL6631028 0.74 PTPN22 (0.50) CYP1A2KDM4EHPGDALOX15RECQL
SCHEMBL645983 0.74 CYP2A6 (0.54) CYP1A2KDM4ETSHRHSD17B10ALDH1A1
SCHEMBL647103 0.74 BACE1 (0.34) CYP1A2ALDH1A1
SCHEMBL466417 0.74 CYP2A6 (0.54) CYP1A2PLAUTSHRHPGDHSD17B10
SCHEMBL2253188 0.74 ALDH1A1 (0.54) CYP1A2CTDSP1PLAUKDM4ETSHR
1-Naphthol SCHEMBL28322906 0.74 CYP1A2 (0.94) CYP1A2CTDSP1PLAUKDM4EMAPKAPK2
1-Naphthol SCHEMBL28123317 0.74 CYP1A2 (0.94) CYP1A2CTDSP1PLAUKDM4EMAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0745719-A2 Use of carbohydrate compounds as auxiliary agents in the dyeing or printing of fibrous materials HOECHST AKTIENGESELLSCHAFT (DE) 1996-12-04 EP claimed
CN-118103357-A FABP4/5 inhibitors, methods of use and methods of preparation 塞洛拉姆股份有限公司 2024-05-28 CN disclosed
CN-117980305-A Spirocyclic pyridine-1, 5-diones exhibiting MNK inhibition and methods of use thereof 4E治疗公司 2024-05-03 CN disclosed
CN-117679487-A Inhibition of pulmonary fibrosis with Nutlin-3a and peptides 得克萨斯州大学系统董事会 2024-03-12 CN disclosed
US-11883386-B2 Prolyl hydroxylase inhibitors and methods of use AKEBIA THERAPEUTICS, INC. (US) 2024-01-30 US disclosed
CN-110201144-B Inhibition of pulmonary fibrosis with Nutlin-3a and peptides 得克萨斯州大学系统董事会 2024-01-02 CN disclosed
CN-117279909-A Novel liver selective polyadenylation polymerase inhibitors and methods of use thereof 巴鲁克斯布伦博格研究所 2023-12-22 CN disclosed
WO-2023172486-A1 METAL POLYMER COMPLEXES METHODS FOR CARBON DIOXIDE CAPTURE LEHIGH UNIVERSITY (US) 2023-09-14 WO disclosed
EP-3768682-B1 2-({2H,3H-[1,4]DIOXINO[2,3-G]QUINOLIN-7-YL}SULFANYL)ACETAMIDE DERIVATIVES AS BCR-ABL KINASE INHIBITORS FOR THE TREATMENT OF CANCER ALLCRON PHARMA INC (US) 2023-07-05 EP disclosed
US-20230201178-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE KREOS CAPITAL VII (UK) LIMITED (GB) 2023-06-29 US disclosed
US-5834501-A TREATING DIABETES OR HYPERLIPEMIA SANKYO COMPANY, LIMITED (JP) 1998-11-10 US disclosed
US-5766267-A USING FIBER REACTIVE DYES HOECHST AKTIENGESELLSCHAFT (DE) 1998-06-16 US disclosed
US-5750681-A Bicyclic beta-lactams and process therefor UNIVERSITY OF NOTRE DAME DU LAC (US) 1998-05-12 US disclosed
US-5739345-A HYPOGLYCEMIC AND ANTIDIABETIC AGENTS SANKYO COMPANY, LIMITED (JP) 1998-04-14 US disclosed
US-5624935-A ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS SANKYO COMPANY, LIMITED 1997-04-29 US disclosed
EP-0745600-A1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-12-04 EP disclosed
EP-0745719-A2 Use of carbohydrate compounds as auxiliary agents in the dyeing or printing of fibrous materials HOECHST AKTIENGESELLSCHAFT (DE) 1996-12-04 EP disclosed
CN-1118781-A Heterocyclic compound with activity against diabetes and preparation and application of same MITSUTAKA CO LTD (JP) 1996-03-20 CN disclosed
EP-0676398-A2 Heterocyclic compounds having anti-diabetic activity, their preparation and their use SANKYO COMPANY LIMITED (JP) 1995-10-11 EP disclosed
US-5216138-A With vinyl sulfonyl group HOECHST AKTIENGESELLSCHAFT (DE) 1993-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11883386-B2 Prolyl hydroxylase inhibitors and methods of use HIF1AN, EGLN3, HIF1A CYP1A2 1465/4885CTDSP1 803/4885PLAU 1093/4885
US-20230201178-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE HIF1AN, EGLN3, HIF1A CYP1A2 1465/4885CTDSP1 803/4885PLAU 1093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.